Literature DB >> 6403048

Distribution and properties of human intestinal diamine oxidase and its relevance for the histamine catabolism.

T Biegański, J Kusche, W Lorenz, R Hesterberg, C D Stahlknecht, K D Feussner.   

Abstract

High activities of diamine oxidase (EC 1.4.3.6) were measured in the intestinal tract of human subjects and of several mammalian species. The enzyme was localized in the mucosa and was distributed primarily in the cytoplasm; the only exception being the guinea-pig where it was located in the particulate fraction. Despite its instability the enzyme from human colonic mucosa was purified 80-fold. During the purification a soluble monoamine oxidase (EC 1.4.3.4) was separated from diamine oxidase. The pH optima of diamine oxidase for putrescine and histamine were 6.6-7.0 and 6.4-6.6, respectively. Short-chain aliphatic diamines were deaminated with the highest reaction velocity, but histamine and N tau-methylhistamine were also excellent substrates. The Km for putrescine was 8.3 x 10(-5) M, for histamine 1.9 x 10(-5) M and for N tau-methylhistamine 9.7 x 10(-5) M. Typical substrates of monoamine oxidase were not deaminated by the enzyme. Aminoguanidine strongly inhibited human intestinal diamine oxidase (IC50 = 1.1 x 10(-8) M). Because of its properties the intestinal diamine oxidase is considered to play a protective role against histamine in diseases such as ischaemic bowel syndrome, mesenteric infarction and ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6403048     DOI: 10.1016/0304-4165(83)90092-2

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  30 in total

1.  Oxymatrine ameliorates L-arginine-induced acute pancreatitis in rats.

Authors:  Zhiqiang Zhang; Yanqing Wang; Ming Dong; Jianchun Cui; Daqing Rong; Qi Dong
Journal:  Inflammation       Date:  2012-04       Impact factor: 4.092

2.  Purification of human intestinal diamine oxidase.

Authors:  H G Schwelberger; J Sattler; E Bodner
Journal:  Inflamm Res       Date:  1996-03       Impact factor: 4.575

3.  Human intestinal diamine oxidase (DAO) activity in Crohn's disease: a new marker for disease assessment?

Authors:  W U Schmidt; J Sattler; R Hesterberg; H D Röher; T Zoedler; H Sitter; W Lorenz
Journal:  Agents Actions       Date:  1990-04

Review 4.  Nitric oxide synthases: structure, function and inhibition.

Authors:  W K Alderton; C E Cooper; R G Knowles
Journal:  Biochem J       Date:  2001-08-01       Impact factor: 3.857

5.  Role of nitric oxide in the circulatory failure and organ injury in a rodent model of gram-positive shock.

Authors:  K M Kengatharan; S J De Kimpe; C Thiemermann
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

6.  Acute necrosis of the intestinal mucosa with high serum levels of diamine oxidase.

Authors:  G Bounous; V Echavé; S J Vobecky; H Navert; A Wollin
Journal:  Dig Dis Sci       Date:  1984-09       Impact factor: 3.199

7.  Aminoguanidine attenuates the delayed circulatory failure and improves survival in rodent models of endotoxic shock.

Authors:  C C Wu; S J Chen; C Szabó; C Thiemermann; J R Vane
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

8.  Structure and inhibition of human diamine oxidase.

Authors:  Aaron P McGrath; Kimberly M Hilmer; Charles A Collyer; Eric M Shepard; Bradley O Elmore; Doreen E Brown; David M Dooley; J Mitchell Guss
Journal:  Biochemistry       Date:  2009-10-20       Impact factor: 3.162

9.  Amine oxidase copper-containing 1 (AOC1) is a downstream target gene of the Wilms tumor protein, WT1, during kidney development.

Authors:  Karin M Kirschner; Julian F W Braun; Charlotte L Jacobi; Lucas J Rudigier; Anja Bondke Persson; Holger Scholz
Journal:  J Biol Chem       Date:  2014-07-17       Impact factor: 5.157

10.  Prediction and validation of enzyme and transporter off-targets for metformin.

Authors:  Sook Wah Yee; Lawrence Lin; Matthew Merski; Michael J Keiser; Aakash Gupta; Youcai Zhang; Huan-Chieh Chien; Brian K Shoichet; Kathleen M Giacomini
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-03       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.